Pfizer Total Long Term Liabilities 2012-2026 | PFE
Pfizer total long term liabilities from 2012 to 2026. Total long term liabilities can be defined as the sum of all non-current liabilities.
- Pfizer total long term liabilities for the quarter ending March 31, 2026 were $79.039B, a 5.58% decline year-over-year.
- Pfizer total long term liabilities for 2024 were $81.904B, a 8.4% decline from 2023.
- Pfizer total long term liabilities for 2023 were $89.418B, a 51.17% increase from 2022.
- Pfizer total long term liabilities for 2022 were $59.149B, a 3.58% decline from 2021.
|
Pfizer Annual Total Long Term Liabilities (Millions of US $) |
|
|---|---|
| 2024 | $81,904 |
| 2023 | $89,418 |
| 2022 | $59,149 |
| 2021 | $61,342 |
| 2020 | $64,836 |
| 2019 | $66,844 |
| 2018 | $63,806 |
| 2017 | $69,714 |
| 2016 | $80,660 |
| 2015 | $72,985 |
| 2014 | $74,358 |
| 2013 | $72,115 |
| 2012 | $74,934 |
| 2011 | $76,472 |
|
Pfizer Quarterly Total Long Term Liabilities (Millions of US $) |
|
|---|---|
| 2025-09-30 | $79,039 |
| 2025-06-30 | $79,357 |
| 2025-03-31 | $80,939 |
| 2024-12-31 | $81,904 |
| 2024-09-30 | $83,707 |
| 2024-06-30 | $84,400 |
| 2024-03-31 | $88,039 |
| 2023-12-31 | $89,418 |
| 2023-09-30 | $86,680 |
| 2023-06-30 | $86,227 |
| 2023-03-31 | $57,819 |
| 2022-12-31 | $59,149 |
| 2022-09-30 | $58,145 |
| 2022-06-30 | $60,410 |
| 2022-03-31 | $61,887 |
| 2021-12-31 | $61,342 |
| 2021-09-30 | $61,418 |
| 2021-06-30 | $63,941 |
| 2021-03-31 | $63,299 |
| 2020-12-31 | $64,836 |
| 2020-09-30 | $79,335 |
| 2020-06-30 | $80,648 |
| 2020-03-31 | $67,108 |
| 2019-12-31 | $66,844 |
| 2019-09-30 | $68,077 |
| 2019-06-30 | $64,244 |
| 2019-03-31 | $66,839 |
| 2018-12-31 | $63,806 |
| 2018-09-30 | $67,161 |
| 2018-06-30 | $62,701 |
| 2018-03-31 | $66,706 |
| 2017-12-31 | $69,714 |
| 2017-09-30 | $82,824 |
| 2017-06-30 | $82,682 |
| 2017-03-31 | $85,174 |
| 2016-12-31 | $80,660 |
| 2016-09-30 | $80,070 |
| 2016-06-30 | $75,492 |
| 2016-03-31 | $70,848 |
| 2015-12-31 | $72,985 |
| 2015-09-30 | $75,897 |
| 2015-06-30 | $69,555 |
| 2015-03-31 | $72,832 |
| 2014-12-31 | $74,358 |
| 2014-09-30 | $73,137 |
| 2014-06-30 | $73,718 |
| 2014-03-31 | $68,950 |
| 2013-12-31 | $72,115 |
| 2013-09-30 | $76,794 |
| 2013-06-30 | $76,908 |
| 2013-03-31 | $77,028 |
| 2012-12-31 | $74,934 |
| 2012-09-30 | $71,357 |
| 2012-06-30 | $72,083 |
| 2012-03-31 | $74,912 |
| 2011-12-31 | $76,472 |
| 2011-09-30 | $77,746 |
| 2011-06-30 | $76,465 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $153.074B | $62.579B |
| Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $887.629B | 38.81 |
| Johnson & Johnson (JNJ) | United States | $574.358B | 22.08 |
| AbbVie (ABBV) | United States | $367.673B | 20.79 |
| Roche Holding AG (RHHBY) | Switzerland | $318.782B | 0.00 |
| Merck (MRK) | United States | $299.893B | 13.54 |
| Novartis AG (NVS) | Switzerland | $293.951B | 17.16 |
| Novo Nordisk (NVO) | Denmark | $167.527B | 9.60 |
| Sanofi (SNY) | France | $114.048B | 10.56 |
| Bayer (BAYRY) | Germany | $46.178B | 8.70 |
| Innoviva (INVA) | United States | $1.760B | 5.88 |